XML 21 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value of Financial Instruments
3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments

4. Fair Value of Financial Instruments

Financial instruments reported at fair value on a recurring basis include cash equivalents and marketable securities. The following tables present the fair value of cash equivalents and marketable securities in accordance with the hierarchy discussed in Note 2 (in thousands): 

 

 

 

Quoted

 

 

Significant

 

 

 

 

 

 

 

 

 

 

 

prices

 

 

other

 

 

Significant

 

 

 

 

 

 

 

in active

 

 

observable

 

 

unobservable

 

 

 

 

 

 

 

markets

 

 

inputs

 

 

inputs

 

 

 

 

 

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

 

Total

 

March 31, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market mutual funds

 

$

 

 

$

240,240

 

 

$

 

 

$

240,240

 

Total cash equivalents

 

 

 

 

 

240,240

 

 

 

 

 

 

240,240

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government and federal agency securities

 

 

 

 

 

7,589

 

 

 

 

 

 

7,589

 

Certificates of deposit

 

 

 

 

 

1,489

 

 

 

 

 

 

1,489

 

Corporate bonds

 

 

 

 

 

352,890

 

 

 

 

 

 

352,890

 

Municipal securities

 

 

 

 

 

3,028

 

 

 

 

 

 

3,028

 

Total marketable securities

 

 

 

 

 

364,996

 

 

 

 

 

 

364,996

 

Total cash equivalents and marketable securities

 

$

 

 

$

605,236

 

 

$

 

 

$

605,236

 

 

 

 

Quoted

 

 

Significant

 

 

 

 

 

 

 

 

 

 

 

prices

 

 

other

 

 

Significant

 

 

 

 

 

 

 

in active

 

 

observable

 

 

unobservable

 

 

 

 

 

 

 

markets

 

 

inputs

 

 

inputs

 

 

 

 

 

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

 

Total

 

December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market mutual funds

 

$

 

 

$

96,307

 

 

$

 

 

$

96,307

 

Total cash equivalents

 

 

 

 

 

96,307

 

 

 

 

 

 

96,307

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government and federal agency securities

 

 

 

 

 

12,804

 

 

 

 

 

 

12,804

 

Certificates of deposit

 

 

 

 

 

1,990

 

 

 

 

 

 

1,990

 

Corporate bonds

 

 

 

 

 

166,292

 

 

 

 

 

 

166,292

 

Municipal securities

 

 

 

 

 

3,037

 

 

 

 

 

 

3,037

 

Total marketable securities

 

 

 

 

 

184,123

 

 

 

 

 

 

184,123

 

Total cash equivalents and marketable securities

 

$

 

 

$

280,430

 

 

$

 

 

$

280,430

 

 

Management estimates that the carrying amounts of its current accounts receivable, accounts payable and accrued expenses and other current liabilities approximate fair value due to the short-term nature of those instruments. Accounts receivable which contain non-current portions are recorded at their present values using a discount rate that is based on prevailing market rates and the credit profile of the licensee on the date the amounts are initially recorded. Management does not believe there have been any significant changes in market conditions or credit quality that would cause the discount rates initially used to be materially different from those that would be used as of March 31, 2021 to determine the present value of the receivables. Accordingly, management estimates that the carrying value of its non-current accounts receivable approximates the fair value of those instruments.

Non-marketable equity securities are measured at cost less impairment, adjusted for observable price changes for identical or similar investments of the same issuer. As of March 31, 2021 and December 31, 2020, non-marketable equity securities had a carrying value of $1.1 million and were included in other assets on the consolidated balance sheets. The Company did not identify any observable price changes or changes in circumstances that would have had an adverse effect on the fair value of the securities as of March 31, 2021 or December 31, 2020. No remeasurements or impairment losses were recorded on non-marketable equity securities during the three months ended March 31, 2021 and 2020.